West Pharma (WST) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $392.15 -0.48%
Revenue Growth %: +2.8%
Financial Fact:
Net income: 37.6M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +2.8%
Financial Fact:
Net income: 37.6M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
West Pharmaceutical Services, Inc. (NYSE: WST) reported Q2 EPS of $0.52, $0.05 better than the analyst estimate of $0.47. Revenue for the quarter came in at $368.9 million versus the consensus estimate of $368.6 million.
West Pharmaceutical Services, Inc. reaffirmed FY2014 guidance.
For earnings history and earnings-related data on West Pharmaceutical Services, Inc. (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI chip sell-off is ‘unmoored from fundamentals,’ LYNX says
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
